On July 7, Hansoh Pharmaceutical fell 3.24% in regular trading, trading at 32.56 HKD/share, with turnover of approximately 79.67 million HKD. The decline came as the broader pharmaceutical sector pulled back following a strong rally in the prior session.
The pharmaceutical sector experienced widespread weakness, with sector peers declining in tandem: CSPC Pharmaceutical fell 3.28%, Hengrui Medicine fell 2.47%, Asymchem fell 2.60%, SBP Group fell 2.38%, and Luye Pharma fell 1.48%. Notably, the sector had surged the previous trading day on July 6, when China Biopharmaceutical rose 11.18%, CSPC gained 6.12%, and Hansoh itself rose 3.74%, suggesting today's retreat represents a sector-wide pullback from elevated levels.
On the company front, Hansoh's innovation pipeline catalysts have been densely released in recent weeks, including clinical trial approvals for HS-20136-2 injection targeting type 2 diabetes and weight management, as well as NDA acceptances for its GLP-1/GIP dual-agonist weight-loss drug olatorepatide and HS-10568 injection. No new negative company-specific news was identified.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
